SCHEMBL1928259

SCHEMBL1928259

COc1cc(C(C)=O)cc(OC)c1OC(C)=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.62
TUBB4A P04350 3/20 0.53
TUBB P07437 3/20 0.53
TUBA3C P0DPH7 3/20 0.53
TUBA1B P68363 3/20 0.53
TUBA4A P68366 3/20 0.53
TUBB4B P68371 3/20 0.53
TUBB3 Q13509 3/20 0.53
TUBB2A Q13885 3/20 0.53
TUBB8 Q3ZCM7 3/20 0.53
TUBA3E Q6PEY2 3/20 0.53
TUBA1A Q71U36 3/20 0.53
TUBA1C Q9BQE3 3/20 0.53
TUBB6 Q9BUF5 3/20 0.53
TUBB2B Q9BVA1 3/20 0.53
TUBB1 Q9H4B7 3/20 0.53
TSHR P16473 1/20 0.51
TOP1 P11387 3/20 0.49
TNFSF11 O14788 1/20 0.48
GRIN2D O15399 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24106215 0.89 LMNA (0.55) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL24106208 0.88 LMNA (0.53) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL668055 0.86 TSHR (0.64) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL290542 0.85 LMNA (0.69) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL668245 0.85 TUBB4A (0.50) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL23467799 0.85 TUBB1 (0.50) LMNATUBB4ATUBBTUBA3CTUBA1B
Hydrochloric Acid SCHEMBL29142671 0.83 LMNA (0.67) LMNATUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3326825 0.82 TUBB4A (0.63) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13775501 0.82 ACHE (0.58) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL15266000 0.82 ALOX5 (0.64) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814319-B9 POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT JOHNSON & JOHNSON VISION CARE (US) 2025-01-01 EP disclosed
EP-3814319-B1 POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT JOHNSON & JOHNSON VISION CARE (US) 2024-08-14 EP disclosed
US-11970431-B2 Polymerizable absorbers of UV and high energy visible light JOHNSON & JOHNSON VISION CARE, INC. (US) 2024-04-30 US disclosed
US-20210309600-A1 POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT JOHNSON & JOHNSON VISION CARE (US) 2021-10-07 US disclosed
US-20210309600-A1 POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT JOHNSON & JOHNSON VISION CARE (US) 2021-10-07 US disclosed
US-11046636-B2 Polymerizable absorbers of UV and high energy visible light JOHNSON & JOHNSON VISION CARE, INC. (US) 2021-06-29 US disclosed
US-11046636-B2 Polymerizable absorbers of UV and high energy visible light JOHNSON & JOHNSON VISION CARE, INC. (US) 2021-06-29 US disclosed
EP-3814319-A1 POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT Johnson & Johnson Vision Care, Inc. (US) 2021-05-05 EP disclosed
CN-112334444-A Polymerizable absorbers for UV and high energy visible light 强生视力健公司 2021-02-05 CN disclosed
EP-1589007-B1 5-membered heterocycle derivatives, production thereof and their use as medicaments IPSEN PHARMA (FR) 2015-06-03 EP disclosed
US-7291641-B2 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-11-06 US disclosed
US-20070179153-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) 2007-08-02 US disclosed
US-20070179153-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) 2007-08-02 US disclosed
US-20070179153-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) 2007-08-02 US disclosed
US-20070054900-A1 4-Phenlthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy SOCIETE DE CONSEILS DE RECHERCHES ET (FR) 2007-03-08 US disclosed
US-20070021390-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SCRAS 2007-01-25 US disclosed
US-20070021390-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SCRAS 2007-01-25 US disclosed
US-20070021390-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SCRAS 2007-01-25 US disclosed
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments IPSEN PHARMA S.A.S. (FR) 2005-02-17 US disclosed
US-20040132788-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021390-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments PARK7, SNCA, COMT LMNA 2727/4885TUBB4A 181/4885TUBB 152/4885
US-20070179153-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments PARK7, SNCA, SDHA LMNA 2628/4885TUBB4A 85/4885TUBB 63/4885
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments OXER1, OPRL1, OPRK1 LMNA 4096/4885TUBB4A 1442/4885TUBB 1032/4885
US-20040132788-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments OPRK1, HCN1, P2RX7 LMNA 3964/4885TUBB4A 717/4885TUBB 837/4885
US-11970431-B2 Polymerizable absorbers of UV and high energy visible light F12, RAD54L, RAD51 LMNA 1318/4885TUBB4A 3304/4885TUBB 4004/4885
US-11046636-B2 Polymerizable absorbers of UV and high energy visible light F12, IK, RAD51 LMNA 1117/4885TUBB4A 3585/4885TUBB 4092/4885
US-20070054900-A1 4-Phenlthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy TPMT, P2RX4, CACNA1I LMNA 3612/4885TUBB4A 453/4885TUBB 1072/4885
US-20210309600-A1 POLYMERIZABLE ABSORBERS OF UV AND HIGH ENERGY VISIBLE LIGHT F12, RAD54L, RAD51 LMNA 1318/4885TUBB4A 3304/4885TUBB 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.